Axa
ADVM

Axa’s Adverum Biotechnologies ADVM Stock Holding History

Axa’s Portfolio ADVM Stock Details ADVM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-17,525
Closed -$918K – 1272
2019
Q1 		$918K Buy
17,525
+620
+4% +$25.1K ﹤0.01% 998
2018
Q4 		$533K Hold
16,905
– – ﹤0.01% 1076
2018
Q3 		$1.02M Buy
16,905
+476
+3% +$26.7K ﹤0.01% 1031
2018
Q2 		$871K Buy
16,429
+12,449
+313% +$749K ﹤0.01% 1036
2018
Q1 		$231K Buy
+3,980
New +$248K ﹤0.01% 1301
2016
Q1 		– Sell
-69,229
Closed -$6.59M – 1318
2015
Q4 		$6.59M Sell
69,229
-1,456
-2% -$128K 0.03% 486
2015
Q3 		$5.82M Buy
70,685
+51,066
+260% +$6.52M 0.02% 528
2015
Q2 		$3.19M Buy
19,619
+4,354
+29% +$1.47M 0.01% 686
2015
Q1 		$6.18M Buy
15,265
+10,913
+251% +$4.61M 0.03% 531
2014
Q4 		$2.35M Buy
+4,352
New +$1.68M 0.01% 744

Other funds holding ADVM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Axa's ADVM Position: Q2 2019 in Review

Axa sold out of Adverum Biotechnologies (ADVM) in Q2 2019, closing a stake of 17,525 shares — an estimated $918K sold.

Axa first reported a position in ADVM in Q4 2014 and held it in 10 quarters. The position peaked at $6.59M in Q4 2015. 94 funds tracked by Wall St. Rank hold ADVM as of Q2 2019.

  • Axa reported no remaining Adverum Biotechnologies position as of Q2 2019 after selling out during the quarter.
  • Axa sold 17,525 Adverum Biotechnologies shares in Q2 2019, an estimated $918K.
  • Axa first reported a position in Adverum Biotechnologies in Q4 2014 and held it in 10 quarters.
  • Axa's Adverum Biotechnologies position peaked at $6.59M in Q4 2015.
  • 94 funds tracked by Wall St. Rank held Adverum Biotechnologies as of Q2 2019.

Based on Axa's 13F filing for Q2 2019, filed 13 Aug 2019.